Currently, there are some PDE4 inhibitors in clinical trials for different neurological disorders (Table 4) such as Alzheimer’s disease (AD), fragile X syndrome, depression and Huntington’s disease [23]. Here, PDE4A is linked to depressive symptom measurement.